168 related articles for article (PubMed ID: 23050879)
1. Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas.
Matsutani T; Hiwasa T; Takiguchi M; Oide T; Kunimatsu M; Saeki N; Iwadate Y
J Exp Clin Cancer Res; 2012 Oct; 31(1):85. PubMed ID: 23050879
[TBL] [Abstract][Full Text] [Related]
2. Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas.
Adachi-Hayama M; Adachi A; Shinozaki N; Matsutani T; Hiwasa T; Takiguchi M; Saeki N; Iwadate Y
BMC Cancer; 2014 Jun; 14():452. PubMed ID: 24946857
[TBL] [Abstract][Full Text] [Related]
3. Profound tumor-specific Th2 bias in patients with malignant glioma.
Shimato S; Maier LM; Maier R; Bruce JN; Anderson RC; Anderson DE
BMC Cancer; 2012 Nov; 12():561. PubMed ID: 23186108
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of a novel glioma antigen, EFTUD1.
Saito K; Iizuka Y; Ohta S; Takahashi S; Nakamura K; Saya H; Yoshida K; Kawakami Y; Toda M
Neuro Oncol; 2014 Dec; 16(12):1618-29. PubMed ID: 25015090
[TBL] [Abstract][Full Text] [Related]
5. Autologous serologic responses in glioma patients. Correlation with tumor grade and survival.
Kornblith PL; Coakham HB; Pollock LA; Wood WC; Green SB; Smith BH
Cancer; 1983 Dec; 52(12):2230-5. PubMed ID: 6640493
[TBL] [Abstract][Full Text] [Related]
6. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
7. Serological analysis of tumor antigens in malignant glioma patients.
Yoshida S; Tanaka R; Ono K
Neurol Med Chir (Tokyo); 1991 Sep; 31(9):559-62. PubMed ID: 1723168
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas.
Schmits R; Cochlovius B; Treitz G; Regitz E; Ketter R; Preuss KD; Romeike BF; Pfreundschuh M
Int J Cancer; 2002 Mar; 98(1):73-7. PubMed ID: 11857388
[TBL] [Abstract][Full Text] [Related]
9. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
[TBL] [Abstract][Full Text] [Related]
10. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
11. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
[TBL] [Abstract][Full Text] [Related]
12. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in neuro-oncology.
Stavrou D
Neurosurg Rev; 1990; 13(1):7-18. PubMed ID: 2181345
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment
Zha C; Meng X; Li L; Mi S; Qian D; Li Z; Wu P; Hu S; Zhao S; Cai J; Liu Y
Cancer Biol Med; 2020 Feb; 17(1):154-168. PubMed ID: 32296583
[No Abstract] [Full Text] [Related]
15. Serum GFAP autoantibody as an ELISA-detectable glioma marker.
Wei P; Zhang W; Yang LS; Zhang HS; Xu XE; Jiang YH; Huang FP; Shi Q
Tumour Biol; 2013 Aug; 34(4):2283-92. PubMed ID: 23589055
[TBL] [Abstract][Full Text] [Related]
16. Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.
Shimato S; Natsume A; Wakabayashi T; Tsujimura K; Nakahara N; Ishii J; Ito M; Akatsuka Y; Kuzushima K; Yoshida J
J Neurosurg; 2008 Jul; 109(1):117-22. PubMed ID: 18590440
[TBL] [Abstract][Full Text] [Related]
17. Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls.
Fischer U; Struss AK; Hemmer D; Pallasch CP; Steudel WI; Meese E
Clin Exp Immunol; 2001 Nov; 126(2):206-13. PubMed ID: 11703362
[TBL] [Abstract][Full Text] [Related]
18. Autologous humoral response to human gliomas and analysis of certain cell surface antigens: in vitro study with the use of microcytotoxicity and immune adherence assays.
Coakham HB; Kornblith PL; Quindlen EA; Pollock LA; Wood WC; Hartnett LC
J Natl Cancer Inst; 1980 Feb; 64(2):223-33. PubMed ID: 6153405
[TBL] [Abstract][Full Text] [Related]
19. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
[TBL] [Abstract][Full Text] [Related]
20. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Iwamoto FM; Hottinger AF; Karimi S; Riedel E; Dantis J; Jahdi M; Panageas KS; Lassman AB; Abrey LE; Fleisher M; DeAngelis LM; Holland EC; Hormigo A
Neuro Oncol; 2011 Nov; 13(11):1244-51. PubMed ID: 21831900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
